Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial - le Tourneau, C; Delord, JP; Gonçalves, A (Lancet Oncol, 2015)
et al.